Document Detail

Evaluation of circulating adipokines and abdominal obesity as predictors of significant myocardial ischemia using gated single-photon emission computed tomography.
Jump to Full Text
MedLine Citation:
PMID:  24842767     Owner:  NLM     Status:  In-Data-Review    
OBJECTIVE: Coronary artery disease (CAD) is associated with abdominal obesity and metabolic syndrome. Adipocytes secrete adipokines, including the newly discovered adipocyte fatty acid binding protein (A-FABP) and chemerin. Adipokines contribute to the pathogenesis of CAD. In patients with CAD, the presence of significant ischemia predicts adverse outcomes. It is unknown whether adipokines can be better predictors of the presence of significant myocardial ischemia than conventional risk factors. This study aimed to compare adipokines with clinical risk factors and abdominal obesity as predictive factors for significant myocardial ischemia.
METHODS: One hundred and ninety-six adults with suspected, but unproven, CAD were consecutively enrolled. The main measures were clinical and biochemical parameters and stress myocardial perfusion imaging with gated myocardial perfusion single-photon emission computed tomography (SPECT), with computed tomography (CT) attenuation correction. The abdominal visceral fat area was examined using a hybrid SPECT/CT scanner. Serum levels of high-sensitivity C-reactive protein (hs-CRP) and adipokines (adiponectin, A-FABP, and chemerin) were evaluated.
RESULTS: A-FABP levels correlated significantly with adiponectin, hs-CRP, body mass index, waist circumference, and visceral fat area. A-FABP was significantly associated with metabolic syndrome (OR 3.2, 95% CI 1.6-6.4, p = 0.001), significant myocardial ischemia (OR 1.9, 95% CI 1.0-3.4, p = 0.05), and stress lung-to-heart ratio (β = 0.03, p = 0.03) on SPECT. Chemerin was significantly associated with serum triglyceride levels but not with metabolic syndrome, significant ischemia, or stress lung-to-heart ratio on SPECT. A-FABP was better at detecting significant inducible ischemia than other biomarkers, although this was a modest improvement (area under ROC curve 0.579, 95% CI 0.46-0.69).
CONCLUSIONS: Serum A-FABP concentrations correlate significantly with visceral fat area, metabolic syndrome, and predicted significant myocardial ischemia on SPECT. This may help to more accurately assess CAD risk, especially in patients with metabolic syndrome.
Chi-Sheng Hung; Yen-Wen Wu; Jei-Yie Huang; Pei-Ying Hsu; Ming-Fong Chen
Related Documents :
7092777 - Metabolic and haemodynamic responses to adrenaline in normal dogs.
6869307 - Comparative study of the arterial and lacunary systems of the ventricular myocardium of...
24774937 - Transient left ventricular apical ballooning without coronary stenoses syndrome: import...
618627 - Effect of dopamine on hemodynamics and myocardial metabolism in shock following acute m...
15605677 - The use of recombinant human b-type natriuretic peptide (nesiritide) in the management ...
6181287 - The pathophysiologic role of myocardial depressant factor as a mediator of circulatory ...
Publication Detail:
Type:  Journal Article     Date:  2014-05-19
Journal Detail:
Title:  PloS one     Volume:  9     ISSN:  1932-6203     ISO Abbreviation:  PLoS ONE     Publication Date:  2014  
Date Detail:
Created Date:  2014-05-20     Completed Date:  -     Revised Date:  -    
Medline Journal Info:
Nlm Unique ID:  101285081     Medline TA:  PLoS One     Country:  United States    
Other Details:
Languages:  eng     Pagination:  e97710     Citation Subset:  IM    
Export Citation:
APA/MLA Format     Download EndNote     Download BibTex
MeSH Terms

From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine

Full Text
Journal Information
Journal ID (nlm-ta): PLoS One
Journal ID (iso-abbrev): PLoS ONE
Journal ID (publisher-id): plos
Journal ID (pmc): plosone
ISSN: 1932-6203
Publisher: Public Library of Science, San Francisco, USA
Article Information
Download PDF
Copyright: 2014 Hung et al
Received Day: 12 Month: 1 Year: 2014
Accepted Day: 23 Month: 4 Year: 2014
collection publication date: Year: 2014
Electronic publication date: Day: 19 Month: 5 Year: 2014
Volume: 9 Issue: 5
E-location ID: e97710
PubMed Id: 24842767
ID: 4026442
Publisher Id: PONE-D-14-01290
DOI: 10.1371/journal.pone.0097710

Evaluation of Circulating Adipokines and Abdominal Obesity as Predictors of Significant Myocardial Ischemia Using Gated Single-Photon Emission Computed Tomography Alternate Title:A-FABP Associated with Significant Myocardial Ischemia
Chi-Sheng Hung1
Yen-Wen Wu1234*
Jei-Yie Huang2
Pei-Ying Hsu5
Ming-Fong Chen1
Xin-Liang Maedit1 Role: Editor
1Department of Internal Medicine (Cardiology Division), National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
2Department of Nuclear Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan
3Cardiology Division of Cardiovascular Medical Center and Department of Nuclear Medicine, Far Eastern Memorial Hospital, New Taipei City, Taiwan
4National Yang-Ming University School of Medicine, Taipei, Taiwan
5Department of Nuclear Medicine, National Taiwan University Hospital, Yun-Lin Branch, Douliou City, Taiwan
Thomas Jefferson University, United States of America
Correspondence: * E-mail:
[conflict] Competing Interests: The authors have declared that no competing interests exist.
Contributed by footnote: Conceived and designed the experiments: C-SH Y-WW M-FC. Performed the experiments: C-SH Y-WW J-YH P-YH. Analyzed the data: C-SH Y-WW J-YH P-YH M-FC. Contributed reagents/materials/analysis tools: C-SH Y-WW J-YH P-YH. Wrote the paper: C-SH Y-WW.


Obesity, a state of excessive adipose tissue, has long been known to be a risk factor for the development of cardiovascular disease [1], [2]. Adipose tissue has been traditionally considered a fat-storage organ, but is now known to have an active role in systemic metabolism through the active secretion of adipokines. These adipokines can target distant organs and have major effects on body weight, energy storage, insulin sensitivity, glucose regulation, and the inflammatory response. Evidence also supports the notion that the adipose tissue of different body compartments has different adipokine secretion profiles [3]. Among the fat storage compartments in the body, visceral fat has been found to be an important source of proinflammatory adipokines [4], [5]. Visceral fat is associated with an increased risk of atherosclerosis compared to subcutaneous fat [6], [7]. According to these findings, the dysregulation of adipokines has been proposed as a potential link between obesity and cardiovascular disease [8]. Therefore, it is important to clarify the roles of different adipokines in the mechanism of metabolic disorders.

Two novel adipokines, adipocyte fatty acid binding protein (A-FABP) and chemerin, have been recently identified to be associated with adipose tissue, metabolic syndrome, and cardiovascular disease. A-FABP is reported to be associated with coronary artery disease (CAD) [9][11] and as a predictor for increased risk of cardiovascular death during long-term follow-up (hazard ratio, 1.75; 95% CI, 1.17–2.62, p = 0.007) [12]. Chemerin is involved in multiple aspects of various biological processes, including immunity, obesity, inflammation, and insulin resistance [13]. Serum chemerin has also been reported to be associated with the severity of coronary atherosclerosis [14]. However, the clinical utility of these two adipokines in the diagnosis or management of CAD has not yet been thoroughly explored.

In patients with CAD, the severity of inducible myocardial ischemia is an important predictor of adverse outcomes [15]. Myocardial perfusion imaging performed with thallium-201 (201Tl) reveals the severity of myocardial ischemia and helps identify patients who have increased risk of cardiac death or non-fatal myocardial infarction [16]. Patients with an ischemic area that is greater than 10% of the left ventricular myocardium, as detected by myocardial perfusion imaging, have better outcomes with revascularization than with medical therapy only [17]. Despite the fact that clinical scores (e.g., Framingham risk score) are useful to estimate the risk for CAD, no serum biomarker has been reported to reliably identify patients with significant myocardial ischemia.

In view of the emerging role of A-FABP and chemerin in patients with CAD, we designed this cross-sectional study to explore the presence of associations of these two adipokines with the amount of abdominal visceral fat, and with the severity of myocardial ischemia. We hypothesized that serum A-FABP and chemerin concentrations indeed follow these correlations, and that they would serve as useful biomarkers for the identification of patients with significant myocardial ischemia who may benefit from revascularization.

Ethical statement

The study was approved by the Institutional Review Board of the National Taiwan University Hospital and complies with the Helsinki Declaration. Written informed consent was obtained from each patient before enrollment.

Study design

Between January 2008 and December 2011, we enrolled 196 patients with typical symptoms indicative of ischemic heart disease at the Cardiovascular Center of National Taiwan University Hospital, Yun-Lin Branch, Taiwan. Subjects with the following conditions were excluded from this study: unstable vital signs, acute coronary syndrome, a history of myocardial infarction (MI), severe heart failure (NYHA functional class 4), severe asthma or chronic obstructive pulmonary disease, high-degree atrial-ventricular conduction block without a pacemaker, or pregnancy. In addition to clinical and biochemical parameters, all subjects received anthropometric evaluation and underwent nuclear myocardial perfusion imaging. Waist and hip circumferences were measured to the nearest 0.1 cm. Blood pressure was recorded using a mercury sphygmomanometer to the nearest 2 mmHg with the arm supported at heart level after sitting quietly for 10 minutes. Plasma glucose and the fasting serum total cholesterol, triglycerides, high-density lipoprotein (HDL) cholesterol, and low-density lipoprotein (LDL) cholesterol were measured with an automated analyzer (Toshiba TBA 200 FR, Toshiba Medical Systems Co., Ltd., Tokyo, Japan). Plasma glycosylated hemoglobin (HbA1c) was measured using another automated analyzer (HLC-723 G7 HPLC Systems, Tosoh Corporation, Tokyo, Japan). Diabetes was diagnosed according to the 2010 American Diabetes Association (ADA) recommendations (HbA1c≥6.5%, fasting plasma glucose ≥126 mg/dL, or 2-hour plasma glucose after standard 75 g oral glucose tolerance test ≥200 mg/dL) [18]. Metabolic syndrome was defined according to the ATP III study panel, with modification of the waist circumference criteria to match Asian ethnicity, as meeting three or more of the following criteria: 1) high blood pressure: systolic and/or diastolic blood pressure ≥130/85 mmHg or receiving blood pressure-lowering medications, 2) hyperglycemia: fasting plasma glucose ≥100 mg/dL (5.6 mmol/L) or receiving glucose lowering medications, 3) hypertriglyceridemia: fasting plasma triglyceride ≥150 mg/dL (1.69 mmol/L), 4) HDL cholesterol <40 mg/dL in men and <50 mg/dL in women, and 5) waist circumference ≥90 cm in men and ≥80 cm in women [19].

Subjects' samples were collected in potassium-EDTA tubes after overnight fasting and stored at −80°C until assayed. Serum biomarkers were analyzed by commercially available enzyme-linked immunosorbent assay (ELISA) kits as follows: A-FABP (BioVendor Laboratory Medicine, Inc., Brno, Czech Republic), chemerin (Millipore, Corporation, Billerica, MA, USA), adiponectin (B-Bridge, Tokyo, Japan), and hs-CRP (Millipore, Corporation, Billerica, MA, USA). Inter-assay and intra-assay coefficients of variation of all assays were less than 5% and all laboratory work was undertaken by researchers that were blinded to the patients' clinical details.

Nuclear myocardial perfusion imaging

A dipyridamole stress 201Tl single-photon emission tomography (SPECT) was performed within one month after clinical evaluation. Dipyridamole (0.14 mg/kg/min) was intravenously infused over 4 minutes to induce coronary hyperemia. Three minutes after the completion of the infusion, 2.5–3 mCi 201Tl was injected. ECG-gated SPECT (8 frames per cardiac cycle) was acquired 5 minutes and 3–4 hours after 201Tl injection in all patients on a hybrid dual-head SPECT/CT scanner (Symbia T2, Siemens Medical Solutions, Inc. Hoffman Estates, IL, USA) equipped with 2-slice CT. Low-dose CT scans of the chest region were routinely acquired after stress SPECT for attenuation correction [20].

In addition to measuring LV functional parameters and stress lung-to-heart ratio [20], the myocardium was divided into 17 segments and each segment was semi-quantitatively visually scored using a 5-point scoring system (0 =  normal, 1 =  mildly abnormal, 2 =  moderately abnormal, 3 =  severely abnormal, 4 =  absence of tracer uptake). The summed scores at rest (SRS) and after stress (SSS) were obtained by adding the individual segment score at rest and after stress, respectively. The summed difference score (SDS) was calculated by subtracting the SRS from the SSS. The segments with reverse distribution were excluded from the calculation of SDS. The extent of ischemia was expressed as the percentage of ischemic myocardium (SDS/68×100). The extent of ischemia was then classified into 3 levels by the percentage of ischemic myocardium, with 0% being no ischemia, 1%–9% being mild ischemia, and ≥10% being significant ischemia, which evidence suggests is the threshold of ischemia where revascularization shows greater benefit than medical treatment alone [17].

Measurement of abdominal adipose tissue areas

Abdominal adiposity was assessed using the same SPECT/CT scanner throughout the study, with the patient lying in a supine position immediately after stress myocardial perfusion imaging. Twenty-five contiguous 5-mm thick slices (120 kVp, 400 mA, gantry rotation time 500 ms, table feed 3∶1) were acquired, covering 125 mm above the level of S1. The raw data were reconstructed using a 55-cm field-of-view. Subcutaneous fat was defined as the extra-peritoneal fat between the skin and muscle, with attenuation ranging from −195 to −45 Hounsfield units (HU) and a window center of −120 HU to identify pixels containing adipose tissue. In order to separate visceral from subcutaneous fat, the abdominal muscular wall separating the two compartments was manually traced. The visceral adipose tissue (VAT) area and subcutaneous adipose tissue (SAT) area were determined by automatic planimetry at the umbilical level. The intra- and inter-reader reproducibility was high for the SAT and VAT measurements in our laboratory (inter-reader and intra-reader comparisons, all r≥0.98, p<0.0001) [21].

Statistical analysis

All variables are expressed as the mean ± standard deviation (SD) in SI units. Pearson's correlation tests were used to assess the correlations between the metabolic parameters and A-FABP or chemerin after adjusting for age. Diagnostic criteria of significant myocardial ischemia using clinical parameters, serum biomarkers, and abdominal fat areas were developed based on receiver operating characteristic (ROC) analysis. Logistic regression models were used to evaluate associations between significant ischemia and the presence of metabolic syndrome and biomarkers levels. Linear regression analyses were performed to evaluate associations between stress lung-to-heart ratio and biomarker levels.


Overall, 89 women and 97 men were enrolled. The demographic and clinical characteristics of the study subjects are shown in Table 1. The mean age was 63.6 (±10.7) years. Among all subjects, 48% had hypertension, 31% had diabetes, 21% had dyslipidemia, and 67% had metabolic syndrome. Compared to women, men had significantly lower SAT areas (80.2±35.1 cm2 versus 121.4±45.6 cm2, p<0.001), but tended to have higher VAT areas (74.9±31.6 cm2 versus 67.6±26.9 cm2, p = 0.08). The average resting LV ejection fraction was 62.3% (57.6% for men and 67.1% for women, p<0.001), a gender difference that was also observed in our previous report [20], [22]. The mean SSS was 6.7 (7.9 for men and 5.4 for women) and the mean SDS was 3.2 (3.2 for men and 3.1 for women), with no differences between men and women (p≥0.05). The numbers of patients with no ischemia, mild ischemia, and significant ischemia were 47 (25.3%), 114 (61.3%), and 25 (13.4%), respectively.

Age-adjusted correlations of A-FABP or chemerin with metabolic parameters, other adipokines, and abdominal fat areas are listed in Table 2. A-FABP correlated significantly with adiponectin, hs-CRP, body mass index (BMI), waist circumference, and abdominal fat areas in all participants, but did not correlate with lipid profiles. In addition, the correlation of A-FABP with adiponectin and hs-CRP was gender-dependent. No correlations were found between chemerin and hs-CRP, A-FABP, or adiponectin. Chemerin only correlated with triglyceride levels in males.

Table 3 displays the associations between serum A-FABP or chemerin and the presence of metabolic syndrome. In the crude analysis (Model 0), the odds ratios (OR) for metabolic syndrome was 3.2 (1.6–6.4, p = 0.001) with A-FABP and 2.7 (0.8–8.7, p = 0.1) with chemerin. The BMI and VAT areas were also significantly associated with metabolic syndrome (excluding factors directly included in the criteria of metabolic syndrome). Further analyses were performed in different models: Model 1 was adjusted for age, Model 2 was adjusted for age and BMI, and Model 3 was adjusted for age and VAT area. The results revealed significant associations between A-FABP and metabolic syndrome in total participants and in male participants. The associations between chemerin and metabolic syndrome were not significant in these analyses.

Table 4 shows the associations between A-FABP or chemerin and the presence of significant ischemia. In the crude analysis (Model 0), the OR for significant ischemia was 2.0 (1.0–3.9, p = 0.05) with A-FABP and 3.2 (0.6–17.1, p = 0.17) with chemerin. The VAT area, SAT area, serum hs-CRP, and adiponectin concentration were not significantly associated with the presence of significant ischemia. Other parameters that correlated with the presence of significant ischemia included systolic blood pressure (SBP), diastolic blood pressure, and a history of CAD. We adjusted these factors in Models 1–3: Model 1 was adjusted for age, Model 2 was adjusted for age and SBP, and Model 3 was adjusted for age, SBP, and a history of CAD. These adjustments for the covariates revealed significant associations between A-FABP and the presence of significant ischemia in total participants and in female participants. Chemerin, however, showed a significant association with the presence of significant ischemia only in Model 2 for total participants. The diagnostic ability of A-FABP to identify patients with significant ischemia was modest (area under the ROC curve 0.57, 95% CI 0.43–0.71), and the optimal cutoff point determined by the Youden method was 45.6 ng/ml (sensitivity 43.5%, specificity 76.8%). We further evaluated the association between the stress lung-to-heart ratio on SPECT and clinical parameters and biomarkers. In the univariate analyses, waist circumference, A-FABP concentration, and hs-CRP were significantly associated with stress lung-to-heart ratio. To investigate these associations further, multivariate linear regression analyses were performed using stress lung-to-heart ratio as the dependent variable and variables with a p value of less than 0.1 in the univariate regression analysis as independent variables. After adjusting for possible confounding factors, A-FABP concentration was still significantly associated with stress lung-to-heart ratio (Table 5).


We demonstrated significant associations of A-FABP with metabolic syndrome and with significant ischemia in patients with stable angina referred for myocardial perfusion imaging examination. The association was also gender-dependent; women showed a much stronger association with significant ischemia, while men show a stronger association with metabolic syndrome. The associations between A-FABP and SAT and VAT were significant after adjusting for age and gender. However, the association of chemerin with metabolic syndrome or significant ischemia was weak and not statistically significant. Our study is the first to measure serum adipokines, VAT, and myocardial ischemia simultaneously on a hybrid SPECT/CT protocol. Although VAT has been previously reported to correlate strongly with CT coronary atherosclerosis [23], we did not find a significant association between VAT and the presence of significant ischemia. Our data demonstrate a stronger correlation between myocardial ischemia and serum A-FABP compared with the correlation between myocardial ischemia and VAT; these findings support the notion that A-FABP is strongly linked to human coronary atherosclerosis. Although its associations were statistically significant, the predictive ability of A-FABP for significant ischemia was only modest.

A-FABP has been associated with atherosclerosis in animal and clinical studies. A-FABP mRNA and protein are expressed in the VAT of human biopsy specimens [24], and A-FABP protein can be released into the circulation by adipose tissue [25]. A-FABP4 is also implicated in the development of insulin resistance and atherosclerosis in animal studies. In A-FABP knockout mice with comorbid leptin deficiency, the animals became obese compared with those with control mice with leptin deficiency only. Insulin sensitivity, however, improved significantly in the A-FABP knockout mice despite their obesity [26]. In an A-FABP and ApoE double-knockout mouse model, the mean atherosclerotic lesion area in the aorta decreased by 66% in double-knockout mice compared with controls [27]. Recently, several clinical studies have demonstrated an association between A-FABP and coronary atherosclerosis. In a report by Jin et al., the A-FABP concentration was higher in female CAD patients than in non-CAD subjects and was also independently associated with Gensini scores (a coronary artery stenosis score) [9]. Circulating A-FABP concentrations were significantly higher in patients with CAD, and correlated with coronary atherosclerosis index [10] and with the number of diseased coronary vessels [11]. In a multivariate logistic regression analysis, A-FABP concentration was an independent predictor for CAD in women even after adjusting for waist circumference, HbA1c, insulin resistance, LDL, glomerular filtration rate, and N-terminal pro-brain natriuretic peptide [10]. Our results complement these studies and show that A-FABP is not only associated with the presence of CAD but also significantly associated with the presence of clinically significant ischemia. The association remained significant after adjusting for age, blood pressure, and history of CAD. This association was significant in the total participant group and in women but not in men. Although the small patient number in the present study may be responsible for the differences in associations between women and men, a gender-dependent association was also observed in the results of Bao et al. [10]. It is well known that body fat distribution, abdominal adipose tissue in particular, differs between human males and females. Women have less visceral fat accumulation and a lower ratio of VAT to total body fat compared with men [28], [29]. Sexual dimorphism has also been reported for adipokines, including leptin [30], adiponectin [31], and chemerin [32]. These gender differences in adipokines may reflect gender differences in adipocyte function or sex hormone regulation [33]. Our results corroborate previous reports [10], suggesting that A-FABP may have a more prominent role in the pathogenesis of myocardial ischemia in females compared with males. In addition, A-FABP may be involved in atherosclerosis during the advanced stages, when a considerable amount of myocardium is at risk.

We tested the potential clinical use of A-FABP or chemerin in identifying patients with significant ischemia. Current guidelines utilize the presence of significant ischemia as one of the factors that determine if a patient with CAD needs to receive percutaneous coronary intervention [15]. Patients with larger areas of ischemic myocardium are at higher risk for future cardiovascular events, and thus benefit from revascularization. In patients with CAD, biomarkers, such as pro-atrial natriuretic peptides or brain natriuretic peptide (at baseline or during exercise), have been tested to identify the presence of significant ischemia with only partial success [34][36]. According to our results, the ability of A-FABP or chemerin to identify patients with significant ischemia was modest.

Our group has recently reported that serum A-FABP levels are associated with moderate to severe myocardial ischemia and are an independent predictor for heart failure in patients with known CAD [37]. The present study confirmed these results in an independent study population with preserved cardiac function and without a history of MI, extending the scope of A-FABP's role to an earlier CAD stage. Furthermore, compared with myocardial ischemia's association with VAT, measured in the present study by CT, its association with A-FABP was stronger and more consistent. Our findings indicate that A-FABP is not merely a marker of VAT or VAT-related cardio-metabolic risk factors. Preclinical studies have already shown that A-FABP has the ability to promote cholesterol accummulation, inhibit cholesterol efflux, and induce proinflammatory cytokines in macrophages [38]. Taken together, these results suggest that A-FABP may contribute directly to the pathogenesis of coronary atherosclerosis and clinically significant myocardial ischemia.

Heightened chemerin levels have been reported to associate with metabolic syndrome [39] and inflammation [40]. Nevertheless, associations between chemerin and myocardial ischemia are not consistent in the literature. Three studies in Chinese populations reported elevated serum chemerin levels to be associated with the presence of CAD [41][43]. However, in another study of 303 Caucasian patients with chest pain, Lehrke et al. found that serum chemerin levels correlated significantly with inflammatory markers, including hs-CRP, interleukin-6, and tumor necrosis factor-α. Despite this link with inflammation, chemerin did not associate with severity of myocardial ischemia after adjusting for established cardio-metabolic risk factors [44]. Additionally, in a Korean study of 131 patients with known CAD, serum chemerin levels were not independently associated with CAD severity [45]. Our results are in agreement with these last two studies. Possible explanations for these inconsistent data include the different assays used, the different ethnic groups studied, and the different stages of coronary atherosclerosis exhibited by the patients enrolled in the studies. Even in those studies showing significant associations, the chemerin levels between CAD and non-CAD groups overlapped markedly. Taken together, these data and our results suggest that using chemerin to identify patients with significant ischemia is unlikely to be effective.

The present study has several limitations. First, to limit radiation exposure to health individuals, we did not enroll healthy subjects to serve as a control group, hence the serum levels of adipokines in healthy controls were not available in our study. Second, this cross-sectional study design does not allow the inference of a causal relationship between A-FABP and clinically significant ischemia. Third, coronary angiography was not routinely performed in the present study. However, we used ECG-gated SPECT and low-dose CT for attenuation correction, which helped to improve diagnostic accuracy, especially in obese or female subjects [20], [22], [46]. Finally, the present study lacked long-term follow-up to compare patient survival and cardiac events and to further evaluate the biomarkers' prognostic value.


The newly discovered adipokine A-FABP is significantly associated with visceral fat areas, metabolic syndrome, and the presence of significant myocardial ischemia. The association between myocardial ischemia and serum adipokines supports a strong link connecting adipokine imbalance with human coronary atherosclerosis and myocardial ischemia. Using serum A-FABP concentration may help to more accurately assess CAD risk, especially in patients with metabolic syndrome.

We gratefully acknowledge the technical assistance of Ms. Yu-Shuan Hung, Ms. Ru-Yi Tsai, Ms. Chou Hsiao-Fang, and Ms. Wang Wan-Li.

1. Hu FB,, Willett WC,, Li T,, Stampfer MJ,, Colditz GA,, et al. (Year: 2004) Adiposity as compared with physical activity in predicting mortality among women. N Engl J Med351: 2694–270315616204
2. Calle EE,, Thun MJ,, Petrelli JM,, Rodrigues C,, Heath CDW, (Year: 1999) Body mass index and mortality in a prospective cohort of U.S. adults. N Engl J Med341: 1097–110510511607
3. Ouchi N,, Parker JL,, Lugus JJ,, Walsh K, (Year: 2011) Adipokines in inflammation and metabolic disease. Nat Rev Immunol11: 85–9721252989
4. Tilg H,, Moschen AR, (Year: 2006) Adipocytokines: mediators linking adipose tissue, inflammation and immunity. Nat Rev Immunol6: 772–78316998510
5. Gustafson B,, Hammarstedt A,, Andersson CX,, Smith U, (Year: 2007) Inflamed adipose tissue: a culprit underlying the metabolic syndrome and atherosclerosis. Arterioscler Thromb Vasc Biol27: 2276–228317823366
6. See R,, Abdullah SM,, McGuire DK,, Khera A,, Patel MJ,, et al. (Year: 2007) The association of differing measures of overweight and obesity with prevalent atherosclerosis: the Dallas Heart Study. J Am Coll Cardiol50: 752–75917707180
7. Lakka HM,, Lakka TA,, Tuomilehto J,, Salonen JT, (Year: 2002) Abdominal obesity is associated with increased risk of acute coronary events in men. Eur Heart J23: 706–71311977996
8. Rajala MW,, Scherer PE, (Year: 2003) Minireview: The adipocyte—at the crossroads of energy homeostasis, inflammation, and atherosclerosis. Endocrinology144: 3765–377312933646
9. Jin J,, Peng DQ,, Yuan SG,, Zhao SP,, Ning XH,, et al. (Year: 2010) Serum adipocyte fatty acid binding proteins and adiponectin in patients with coronary artery disease: the significance of A-FABP/adiponectin ratio. Clinic Chimica Acta411: 1761–1765
10. Bao Y,, Lu Z,, Zhou M,, Li H,, Wang Y,, et al. (Year: 2011) Serum levels of adipocyte fatty acid-binding protein are associated with the severity of coronary artery disease in Chinese women. Plos One6: e1911521552513
11. Hong J,, Gu W,, Zhang Y,, Yan Q,, Dai M,, et al. (Year: 2011) Different association of circulating levels of adipocyte and epidermal fatty acid-binding proteins with metabolic syndrome and coronary atherosclerosis in Chinese adults. Atherosclerosis217: 194–20021492859
12. von Eynatten M,, Breitling LP,, Roos M,, Baumann M,, Rothenbacher D,, et al. (Year: 2012) Circulating adipocyte fatty acid-binding protein levels and cardiovascular morbidity and mortality in patients with coronary heart disease: a 10-year prospective study. Arterioscler Thromb Vasc Biol32: 2327–233522679309
13. Ernst MC,, Sinal CJ, (Year: 2010) Chemerin: at the crossroads of inflammation and obesity. Trends Endocrinol Metab21: 660–66720817486
14. Yan Q,, Zhang Y,, Hong J,, Gu W,, Dai M,, et al. (Year: 2012) The association of serum chemerin level with risk of coronary artery disease in Chinese adults. Endocrine41: 281–28822042485
15. Fihn SD,, Gardin JM,, Abrams J,, Berra K,, Blankenship JC,, et al. (Year: 2012) Guideline for the diagnosis and management of patients with stable ischemic heart disease: a report of the American College of Cardiology Foundation/American Heart Association Task Force on Practice Guidelines, and the American College of Physicians, American Association for Thoracic Surgery, Preventive Cardiovascular Nurses Association, Society for Cardiovascular Angiography and Interventions, and Society of Thoracic Surgeons. J Am Coll Cardiol60: e44–e16423182125
16. Shaw LJ,, Iskandrian AE, (Year: 2004) Prognostic value of gated myocardial perfusion SPECT. J Nucl Cardiol11: 171–18515052249
17. Hachamovitch R,, Hayes SW,, Friedman JD,, Cohen I,, Berman DS, (Year: 2003) Comparison of the short-term survival benefit associated with revascularization compared with medical therapy. Circulation107: 2900–290712771008
18. American Diabetes Association (Year: 2010) Diagnosis and classification of diabetes mellitus. Diabetes Care33 Suppl 1S62–6920042775
19. Tan CE,, Ma S,, Wai D,, Chew SK,, Tai ES, (Year: 2004) Can we apply the National Cholesterol Education Program Adult Treatment Panel definition of the metabolic syndrome to Asians?Diabetes Care27: 1182–118615111542
20. Wang SY,, Cheng MF,, Hwang JJ,, Hung CS,, Wu YW, (Year: 2011) Sex-specific normal limits of left ventricular ejection fraction and volumes estimated by gated myocardial perfusion imaging in adult patients in Taiwan: a comparison between two quantitative methods. Nucl Med Commun32: 113–12021150486
21. Wu YW,, Kao HL,, Huang CL,, Chen MF,, Lin LY,, et al. (Year: 2012) The effects of 3-month atorvastatin therapy on arterial inflammation, calcification, abdominal adipose tissue and circulating biomarkers. Eur J Nucl Med Mol Imaging39: 399–40722109668
22. Wu YT,, Chien CL,, Wang SY,, Yang WS,, Wu YW, (Year: 2013) Gender differences in myocardial perfusion defect in asymptomatic postmenopausal women and men with and without diabetes mellitus. J Womens Health (Larchmt)22: 439–44423600438
23. Mahabadi AA,, Massaro JM,, Rosito GA,, Levy D,, Murabito JM,, et al. (Year: 2009) Association of pericardial fat, intrathoracic fat, and visceral abdominal fat with cardiovascular disease burden: the Framingham Heart Study. Eur Heart J30: 850–85619136488
24. Yoon MY,, Sung JM,, Song CS,, Lee WY,, Rhee EJ,, et al. (Year: 2012) Enhanced A-FABP expression in visceral fat: potential contributor to the progression of NASH. Clin Mol Hepatol18: 279–28623091808
25. Xu A,, Wang Y,, Xu JY,, Stejskal D,, Tam S,, et al. (Year: 2006) Adipocyte fatty acid-binding protein is a plasma biomarker closely associated with obesity and metabolic syndrome. Clin Chem52: 405–41316423904
26. Uysal KT,, Scheja L,, Wiesbrock SM,, Bonner-Weir S,, Hotamisligil GS, (Year: 2000) Improved glucose and lipid metabolism in genetically obese mice lacking aP2. Endocrinology141: 3388–339610965911
27. Makowski L,, Boord JB,, Maeda K,, Babaev VR,, Uysal KT,, et al. (Year: 2001) Lack of macrophage fatty-acid-binding protein aP2 protects mice deficient in apolipoprotein E against atherosclerosis. Nat Med7: 699–70511385507
28. Kvist H,, Chowdhury B,, Grangård U,, Tylén U,, Sjöström L, (Year: 1988) Total and visceral adipose-tissue volumes derived from measurements with computed tomography in adult men and women: predictive equations. Am J Clin Nutr48: 1351–613202084
29. Kotani K,, Tokunaga K,, Fujioka S,, Kobatake T,, Keno Y,, et al. (Year: 1994) Sexual dimorphism of age-related changes in whole-body fat distribution in the obese. Int J Obes Relat Metab Disord18: 207–2128044194
30. Considine RV,, Sinha MK,, Heiman ML,, Kriauciunas A,, Stephens TW,, et al. (Year: 1996) Serum immunoreactive-leptin concentrations in normal weight and obese humans. N Engl J Med334: 292–2958532024
31. Nishizawa H,, Shimomura I,, Kishida K,, Maeda N,, Kuriyama H,, et al. (Year: 2002) Androgens decrease plasma adiponectin, an insulin-sensitizing adipocyte-derived protein. Diabetes51: 2734–274112196466
32. Takahashi M,, Inomata S,, Okimura Y,, Iguchi G,, Fukuoka H,, et al. (Year: 2013) Decreased serum chemerin levels in male Japanese patients with type 2 diabetes: sex dimorphism. Endocr J60: 37–4422986456
33. Karastergiou K,, Smith SR,, Greenberg AS,, Fried SK, (Year: 2012) Sex differences in human adipose tissues - the biology of pear shape. Biol Sex Differ3: 1322651247
34. Nishikimi T,, Mori Y,, Ishimura K,, Tadokoro K,, Yagi H,, et al. (Year: 2004) Association of plasma atrial natriuretic peptide, N-terminal proatrial natriuretic peptide, and brain natriuretic peptide levels with coronary artery stenosis in patients with normal left ventricular systolic function. Am J Med116: 517–52315063812
35. Bocek T,, Morgenthaler NG,, Staub D,, Nusbaumer C,, Christ A,, et al. (Year: 2005) Use of pro-atrial natriuretic peptide in the detection of myocardial infarction. Eur J Clin Invest35: 450–45616008547
36. Zaid G,, Tanchilevitch A,, Rivlin E,, Gropper R,, Rosenschein U,, et al. (Year: 2007) Diagnostic accuracy of serum B-type natriuretic peptide for myocardial ischemia detection during exercise testing with Spect perfusion imaging. Int J Cardiol117: 157–16416997398
37. Huang CL,, Wu YW,, Wu CC,, Lin L,, Wu YC,, et al. (Year: 2013) Association between serum adipocyte fatty-acid binding protein concentrations, left ventricular function and myocardial perfusion abnormalities in patients with coronary artery disease. Cardiovasc Diabetol12: 10523866022
38. Kralisch S,, Fasshauer M, (Year: 2013) Adipocyte fatty acid binding protein: a novel adipokine involved in the pathogenesis of metabolic and vascular disease?Diabetologia56: 10–2123052058
39. Bozaoglu K,, Segal D,, Shields KA,, Cummings N,, Curran JE,, et al. (Year: 2009) Chemerin is associated with metabolic syndrome phenotypes in a Mexican-American population. J Clin Endocrinol Metab94: 3085–308819470637
40. Weigert J,, Neumeier M,, Wanninger J,, Filarsky M,, Bauer S,, et al. (Year: 2010) Systemic chemerin is related to inflammation rather than obesity in type 2 diabetes. Clin Endocrinol (Oxf)72: 342–34819558533
41. Xiaotao L,, Xiaoxia Z,, Yue X,, Liye W, (Year: 2012) Serum chemerin levels are associated with the presence and extent of coronary artery disease. Coron Artery Dis23: 412–41622828724
42. Yan Q,, Zhang Y,, Hong J,, Gu W,, Dai M,, et al. (Year: 2012) The association of serum chemerin level with risk of coronary artery disease in Chinese adults. Endocrine41: 281–28822042485
43. Dong B,, Ji W,, Zhang Y, (Year: 2011) Elevated serum chemerin levels are associated with the presence of coronary artery disease in patients with metabolic syndrome. Intern Med50: 1093–109721576834
44. Lehrke M,, Becker A,, Greif M,, Stark R,, Laubender RP,, et al. (Year: 2009) Chemerin is associated with markers of inflammation and components of the metabolic syndrome but does not predict coronary atherosclerosis. Eur J Endocrinol161: 339–34419497986
45. Hah YJ,, Kim NK,, Kim MK,, Kim HS,, Hur SH,, et al. (Year: 2011) Relationship between chemerin levels and cardiometabolic parameters and degree of coronary stenosis in Korean patients with coronary artery disease. Diabetes Metab J35: 248–25421785745
46. Chien CL,, Wu YW,, Yang WS,, Yang PC,, Su HM,, et al. (Year: 2011) Myocardial perfusion image in asymptomatic postmenopausal women with physical inactivity and overweight. Obesity Facts4: 372–37822166757

[TableWrap ID: pone-0097710-t001] doi: 10.1371/journal.pone.0097710.t001.
Table 1  Baseline characteristics, abdominal fat areas, and myocardial perfusion imaging.
Men (n = 97) Women (n = 89) p
Age, year 62.5 (11.7) 64.8 (9.4) 0.13
Systolic blood pressure, mmHg 132.3 (16.8) 139 (20.6) 0.02
Diastolic blood pressure, mmHg 78.3 (11.5) 78.9 (14.2) 0.76
Waist circumference, cm 95.3 (8.5) 90.7 (10.5) 0.001
Body mass index, kg/m2 26.3 (3.6) 27.3 (4.2) 0.08
Comorbidity, n (%)
Hypertension 38 (39.1%) 52 (58.4%) 0.009
Diabetes 28 (28.8%) 30 (33.7%) 0.48
Dyslipidemia 17 (17.5%) 22 (24.7%) 0.23
Metabolic syndrome 61 (62.9%) 64 (71.9%) 0.19
Smoking 24 (24.7%) 2 (2.2%) <0.001
History of percutaneous coronary intervention 16 (16.5%) 5 (5.6%) 0.02
Medication, n (%)
Calcium channel blocker 21 (21.6%) 26 (29.2%) 0.24
Angiotensin-converting enzyme inhibitor 5 (5.2%) 4 (4.5%) 0.83
Angiotensin II receptor blocker 14 (14.4%) 16 (18%) 0.51
Beta-blocker 22 (22.7%) 14 (15.7%) 0.23
Alpha-blocker 5 (5.2%) 1 (1.1%) 0.12
Aspirin 45 (46.4%) 38 (42.7%) 0.61
Statin 17 (17.5%) 14 (15.7%) 0.74
Fibrate 4 (4.1%) 0 (0%) 0.12
Sulfonylurea 11 (11.3%) 8 (9%) 0.6
Metformin 15 (15.5%) 13 (14.6%) 0.87
Thiazolidinedione 4 (4.1%) 2 (2.2%) 0.47
Insulin 2 (2.1%) 1 (1.1%) 1
Serum biomarkers, mean (SD)
Creatinine, mg/dL 1.34 (1) 1.07 (0.4) 0.02
Total cholesterol, mg/dL 190.8 (44) 207 (94.4) 0.2
LDL-C, mg/dL 113.6 (42.1) 114.9 (48.2) 0.9
HDL-C, mg/dL 41.3 (7.4) 51.7 (24.1) 0.003
Triglyceride, mg/dL 158.1 (90.7) 167.6 (242) 0.76
Fasting glucose, mg/dL 117.3 (41.4) 113.8 (50.9) 0.65
HbA1c, % 6.9 (1.6) 6.9 (1.4) 0.94
hs-CRP, mg/L 4.8 (9.9) 4.4 (17.3) 0.75
A-FABP, ng/mL 22.7 (14.4) 41.9 (35.4) <0.001
Adiponectin, µg/mL 6.6 (3.9) 10.8 (7.9) <0.001
Chemerin, ng/mL 52.7 (14.4) 56.1 (16.8) 0.16
Abdominal computed tomography for fat area, mean (SD)
Visceral adipose tissue area, cm2 74.9 (31.6) 67.6 (26.9) 0.08
Subcutaneous adipose tissue area, cm2 80.2 (35.1) 121.4 (45.6) <0.001
Myocardial perfusion image, mean (SD)
LVEF, % 57.6 (11.9) 67.1 (13.6)
SSS 7.9 (10.4) 5.4 (5.8) 0.08
SDS 3.2 (4.3) 3.1 (3.9) 0.77
Stress lung-to-heart ratio 0.37 (0.07) 0.36 (0.07) 0.42

SD, standard deviation; LDL-C, low-density lipoprotein cholesterol; HDL-C, high-density lipoprotein cholesterol; HbA1c, hemoglobin A1c; hs-CRP, high-sensitivity C-reactive protein; A-FABP, adipocyte fatty acid-binding protein; LVEF, left ventricular ejection fraction; SSS, summed stress score; SDS, summed difference score.

[TableWrap ID: pone-0097710-t002] doi: 10.1371/journal.pone.0097710.t002.
Table 2  Age-adjusted Pearson's correlation between A-FABP and chemerin with metabolic parameters.
Overall Men Women
A-FABP Chemerin A-FABP Chemerin A-FABP Chemerin
Adiponectin 0.301* −0.05 0.0690 −0.1317 0.2526* −0.0631
hs-CRP 0.197* 0.05 0.3486* −0.0685 0.1151 0.1960
Total cholesterol −0.103 0.07 −0.1060 0.2959* −0.1674 −0.0245
Triglyceride 0.164 0.238* 0.2647 0.3313* 0.1254 0.1948
Body mass index 0.445* 0.065 0.3857* 0.0817 0.4608* 0.0234
Waist circumference 0.319* 0.03 0.4522* 0.0723 0.4787* 0.0570
Systolic blood pressure 0.053 0.112 −0.0009 −0.0279 −0.0188 0.2102
Diastolic blood pressure −0.023 0.07 −0.0493 0.1262 −0.0101 0.0382
Visceral adipose tissue area 0.285* 0.14 0.4534* 0.2212* 0.3349* 0.0816
Subcutaneous adipose tissue area 0.481* 0.009 0.4292* 0.1436 0.2927* −0.2190

*p<0.05; hs-CRP, high-sensitivity C-reactive protein; A-FABP, adipocyte fatty acid-binding protein.

[TableWrap ID: pone-0097710-t003] doi: 10.1371/journal.pone.0097710.t003.
Table 3  Predictive ability of A-FABP and chemerin for metabolic syndrome.
Overall OR (95% CI) p Men p Women p
Model 0
A-FABP 3.2 (1.6–6.4) 0.001 6.9 (1.8–25.1) 0.004 2.3 (0.9–5.8) 0.09
Chemerin 2.7 (0.8–8.7) 0.1 2.6 (0.6–12.6) 0.2 2.4 (0.4–14.7) 0.34
Model 1
A-FABP 3.3 (1.6–6.7) 0.001 8.7 (2.2–33.7) 0.002 1.9 (0.7–5.1) 0.2
Chemerin 2.6 (0.8–8.5) 0.12 3.4 (0.7–17.3) 0.1 2.1 (0.3–13.5) 0.4
Model 2
A-FABP 2.3 (1.1–5.0) 0.03 5.5 (1.4–22.7) 0.02 1.3 (0.4–3.9) 0.6
Chemerin 2.4 (0.7–8.5) 0.17 2.85 (0.5–15.6) 0.3 2.1 (0.3–15.7) 0.5
Model 3
A-FABP 2.3 (1.1–5.0) 0.03 5.2 (1.2–22) 0.02 0.9 (0.3–3.0) 0.9
Chemerin 1.7 (0.5–6.0) 0.41 2.0 (0.4–11.4) 0.4 1.3 (0.2–9.5) 0.3

Model 0: no adjustment.

Model 1: adjusted for age.

Model 2: adjusted for age, body mass index.

Model 3: adjusted for age, visceral adipose tissue area.

A-FABP, adipocyte fatty acid-binding protein.

[TableWrap ID: pone-0097710-t004] doi: 10.1371/journal.pone.0097710.t004.
Table 4  Predictive ability of A-FABP and chemerin for significant ischemia.
Overall OR (95% CI) p Men p Women p
Model 0
A-FABP 2.0 (1.0–3.9) 0.05 2.9 (0.8–9.8) 0.09 2.1 (0.8–5.5) 0.14
Chemerin 3.2 (0.6–17.1) 0.17 1.8 (0.2–16.6) 0.58 4.2 (0.4–40.8) 0.22
Model 1
A-FABP 2.3 (1.1–4.8) 0.03 2.7 (0.7–9.6) 0.13 4.1 (1.3–13.7) 0.02
Chemerin 3.7 (0.7–20.2) 0.13 1.4 (0.2–14.1) 0.73 6.6 (0.6–78.7) 0.14
Model 2
A-FABP 2.3 (1.1–4.8) 0.03 2.4 (0.7–8.3) 0.18 4.9 (1.2–18.7) 0.02
Chemerin 5.1 (1.1–24.7) 0.04 1.7 (0.2–16.1) 0.63 7.5 (0.6–102.6) 0.13
Model 3
A-FABP 2.3 (1.1–4.8) 0.04 2.0 (0.6–7.4) 0.30 5.2 (1.3–20.5) 0.02
Chemerin 4.4 (0.8–24.4) 0.09 2.3 (0.2–24.4) 0.48 5.8 (0.6–60.1) 0.14

Model 0: no adjustment.

Model 1: adjusted for age.

Model 2: adjusted for age, systolic blood pressure.

Model 3: adjusted for age, systolic blood pressure, history of coronary artery disease.

A-FABP, adipocyte fatty acid-binding protein.

[TableWrap ID: pone-0097710-t005] doi: 10.1371/journal.pone.0097710.t005.
Table 5  Associations of clinical characteristics and biomarkers with increased stress lung-to-heart ratio during myocardial perfusion imaging.
Univariate Multivariate
Coef. 95% CI p Coef. 95% CI p
Age −0.0004 −0.001–0.0005 0.40 0.0002 −0.01–0.001 0.84
Sex 0.009 −0.0136–0.032 0.43 −0.128 −0.061–0.035 0.60
Waist circumference 0.0015 0.0003–0.0027 0.01 −0.001 −0.0035–0.0013 0.36
Visceral fat area 0.0002 −0.0001–0.0006 0.20
Systolic blood pressure 0.0001 −0.0005–0.0006 0.82
HbA1c 0.0081 −0.0006–0.0168 0.07 0.015 0.002–0.029 0.03
A-FABP* 0.022 0.0016–0.043 0.03 0.056 0.013–0.099 0.01
hs-CRP* 0.009 0.0003–0.017 0.04 0.002 −0.009–0.137 0.67
Chemerin* −0.007 −0.048–0.034 0.73
Adiponectin* −0.0007 −0.22–0.21 0.95

HbA1c, hemoglobin A1c; hs-CRP, high-sensitivity C-reactive protein; A-FABP, adipocyte fatty acid-binding protein.

Article Categories:
  • Research Article
Article Categories:
  • Medicine and Health Sciences
    • Cardiology
    • Metabolic Disorders
    • Radiology and Imaging

Previous Document:  Inhibition of ectopic glioma tumor growth by a potent ferrocenyl drug loaded into stealth lipid nano...
Next Document:  Decreasing the occurrence of intraoperative technical errors through periodic simple show, tell and ...